Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
05/02/2006 | US7037647 Prostate-specific membrane antigen and uses thereof |
05/02/2006 | US7037534 Inactivation of viral infections agents by chemiluminescence activated light-sensitive compounds |
05/02/2006 | US7037524 Oral delivery of a botanical |
05/02/2006 | US7037499 Adjuvant for transcutaneous immunization |
05/02/2006 | US7037498 Antibodies to insulin-like growth factor I receptor |
05/02/2006 | US7037495 Antimicrobial compositions |
05/02/2006 | US7037450 Production scale method of forming microparticles |
05/02/2006 | CA2401191C A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
05/01/2006 | CA2498969A1 Acetylcholine-dependent current as a novel ionic target for atrial fibrillation |
04/27/2006 | WO2006044573A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
04/27/2006 | WO2006044077A2 Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
04/27/2006 | WO2006043710A1 Drug development target protein and target gene, and method of screening |
04/27/2006 | WO2006043701A1 Method of inhibiting phosphorylation of transcriptional factor for gluconeogenesis-associated gene and phosphorylation inhibitor |
04/27/2006 | WO2006043655A1 Medicinal composition for inhalation |
04/27/2006 | WO2006043615A1 Use of immunesuppressant receptor |
04/27/2006 | WO2006043532A1 Therapeutic agent for parkinson's disease |
04/27/2006 | WO2006043510A1 Ester derivative and pharmaceutical use thereof |
04/27/2006 | WO2006043036A2 Treatment of diabetes |
04/27/2006 | WO2006042733A2 Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same |
04/27/2006 | WO2006021412A3 Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
04/27/2006 | WO2006020884A3 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
04/27/2006 | WO2005115359A3 Methods and compositions for the treatment of uveitis |
04/27/2006 | WO2005102296A3 Combinations for the treatment of immunoproliferative skin disorders such as psoriasis |
04/27/2006 | WO2005085421A3 Treatment of spinal conditions |
04/27/2006 | WO2005065712A3 Complexes having adjuvant activity |
04/27/2006 | WO2004021992A3 Delivery of therapeutics to the brain and spinal cord |
04/27/2006 | US20060089404 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
04/27/2006 | US20060089385 Pharmaceutical compositions |
04/27/2006 | US20060089380 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) |
04/27/2006 | US20060089349 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
04/27/2006 | US20060089337 Estrogen replacement regimen |
04/27/2006 | US20060089327 Combinations comprising epothilones and anti-metabolites |
04/27/2006 | US20060089326 Immunostimulatory nucleic acid molecules |
04/27/2006 | US20060089320 Modulation of type IIß phosphoinositide phosphate kinase |
04/27/2006 | US20060089313 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
04/27/2006 | US20060089299 Selective treatment of endothelial somatostatin receptors |
04/27/2006 | US20060088913 Mutation associated with epilepsy |
04/27/2006 | US20060088881 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules |
04/27/2006 | US20060088880 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
04/27/2006 | US20060088824 Used in assays to identify PAP-1/WIP-1 interaction inhibitors; West Nile virus (WNV) |
04/27/2006 | US20060088820 Detecting superantigen activity in a biological sample |
04/27/2006 | US20060088603 Compositions and methods for nutrition supplementation |
04/27/2006 | US20060088561 solidifying agent consists of long chain fatty alcohol; carrier is semi-solid at rest and liquefies upon application of shear forces |
04/27/2006 | US20060088545 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therary of diseases associated therewith |
04/27/2006 | US20060088540 Antagonists and methods for inhibiting angiogenesis |
04/27/2006 | US20060088537 Protein involved in cancer |
04/27/2006 | US20060088535 Method for enhancing long-term memory in a subject and uses thereof |
04/27/2006 | US20060088530 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes |
04/27/2006 | US20060088529 Bispecific monoclonal antibodies to IL-12 and IL-18 |
04/27/2006 | US20060088511 Cancer therapy sensitizer |
04/27/2006 | US20060088502 Drug for reducing side effects in ribavirin interferon combination therapy |
04/27/2006 | US20060088481 Topical oral dosage forms containing bismuth compounds |
04/27/2006 | DE102004040119A1 Agent, useful for e.g. inactivating infectious prion and decontaminating device, instrument or appliance infected with prion, comprises a nano-particle |
04/27/2006 | CA2584398A1 Ester derivative and pharmaceutical use thereof |
04/27/2006 | CA2584385A1 Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same |
04/27/2006 | CA2584209A1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
04/26/2006 | EP1650312A2 Functional assay of high-density lipoprotein |
04/26/2006 | EP1650221A2 Novel compounds |
04/26/2006 | EP1650219A1 Human toll homologues |
04/26/2006 | EP1650188A1 Treatment of tumors with RAR alpha selective retinoid compounds in combination with other anti-tumor agents |
04/26/2006 | EP1649881A1 Drug releasing elastic band and method |
04/26/2006 | EP1649871A1 Retroviral protease inhibitor combinations |
04/26/2006 | EP1649860A1 Pharmaceutical composition for ophthalmic use |
04/26/2006 | EP1649859A1 Pharmaceutical compositions comprising at least one poorly diffusible anticancer drug and a olidodeoxynucleotide immunestimulant |
04/26/2006 | EP1649857A2 New use of glutamate antagonists for the treatment of cancer |
04/26/2006 | EP1649855A1 Medicinal composition |
04/26/2006 | EP1649849A2 Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain. |
04/26/2006 | EP1648910A2 Antisense modulation of stearoyl-coa desaturase expression |
04/26/2006 | EP1648516A2 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
04/26/2006 | EP1648515A1 Chlorthalidone combinations |
04/26/2006 | EP1648514A2 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
04/26/2006 | EP1648493A2 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
04/26/2006 | EP1648477A2 Injection of bone marrow-derived cells and medium for angiogenesis |
04/26/2006 | EP1648476A1 Mouth and/or throat wash |
04/26/2006 | EP1648474A2 Methods and pharmaceutical compositions for healing wounds |
04/26/2006 | EP1648470A1 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor |
04/26/2006 | EP1648439A2 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
04/26/2006 | EP1648437A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
04/26/2006 | EP1648436A1 Ambroxol for treating epilepsy |
04/26/2006 | EP1648435A1 Ambroxol for treating tinnitus |
04/26/2006 | EP1648434A1 Ambroxol for treating chronic nociceptive pains |
04/26/2006 | EP1648428A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
04/26/2006 | EP1648422A2 Treatment and preventi0n of cardiovascular events |
04/26/2006 | EP1648380A2 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants |
04/26/2006 | EP1648376A2 Novel dermatological composition |
04/26/2006 | EP1648364A2 Pharmaceutical compositions for topical application |
04/26/2006 | EP1448281A4 Therapeutic coating for an intravascular implant |
04/26/2006 | EP1421377B1 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
04/26/2006 | EP1414467B1 Topical treatment for mastalgia |
04/26/2006 | EP1361894B1 Use of a polyfunctional active substance mixture as an antagonist against harmful substances contained in tobacco smoke acting as a health protecting agent during smoking |
04/26/2006 | EP1313509B1 Treatment of tumors with acetylenes disubstituted with an heteroaromatic group and a substituted thiochromanyl group in combination with other anti-tumor agents |
04/26/2006 | EP1294689B1 Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt |
04/26/2006 | EP1187918B1 Tek antagonists |
04/26/2006 | EP1185666B1 Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production |
04/26/2006 | EP1066036B1 Agents with serotonin-related activity for the treatment for sleep apnea |
04/26/2006 | EP1009829B1 Adipocyte-specific protein homologs |
04/26/2006 | EP0841949B1 Use of saccharide conjugates |
04/26/2006 | CN1764477A Devices and compositions containing boron and silicon for use in neutron capture therapy |
04/26/2006 | CN1764441A Formulations comprising tolterodine and cocoa powder and use thereof |
04/26/2006 | CN1764440A Formulations comprising an active ingredient and cocoa powder and use thereof |